drugset
drugset / Trial / NCT04452669

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

NCT04452669 ↗

Phase 2 Completed 11 enrolled Aerogen Pharma Limited Ohio State University · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.

Timeline

Start
2020-09-15
Primary completion
2021-06-29
Completion
2021-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject epoprostenol Other / unclassified — Inhaled

Indications

COVID-19